Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -8579.24%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-8579.24%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$415.34M
EBITDA Margin
39.39%
TTM Avg
8.38%
3Y Avg
8.38%
5Y Avg
8.38%
Market Cap
$412.90M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$421.20M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$398.58M
EBITDA Margin
-1.71%
TTM Avg
-2.46%
3Y Avg
-6.59%
5Y Avg
-11.17%
Market Cap
$402.34M
EBITDA Margin
-59.97%
TTM Avg
-74.12%
3Y Avg
-94.06%
5Y Avg
-94.06%
Market Cap
$398.05M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.16M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$429.11M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $415.84M | -8579.24% | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $415.34M | 39.39% | 8.38% | 8.38% | 8.38% |
| Shoulder Innovations, Inc. (SI)vs › | $412.90M | -48.80% | -44.09% | -45.35% | -45.35% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $421.20M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $398.58M | -1.71% | -2.46% | -6.59% | -11.17% |
| Carlsmed, Inc. (CARL)vs › | $402.34M | -59.97% | -74.12% | -94.06% | -94.06% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $398.05M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $438.16M | -232.13% | -495.69% | -578.57% | -532.48% |
| NeoGenomics, Inc. (NEO)vs › | $429.11M | 0.24% | -1.36% | -6.49% | -5.53% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $389.64M | -403.32% | -429.38% | -429.38% | -429.38% |
Gross Margin
0.0%
EBITDA Margin
-8579.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-06-30 | -2088.32% |
| 2018-06-30 | 11.67% |
